Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCTBiotechnology
+$0.15 today
- Market cap
- $231.73M
- Beta
- 2.35
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$2.77
Volume 0.64M
Average 0.43M
ARCT Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $658K fell 17.9% year over year, behind the -16.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.5% from the prior quarter. Over 3 fiscal years it compounded at +25.6% a year.
Context
- Depreciation & amortization amounted to 4.5% of revenue in FY2025, up 1.9 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -17.9% toward the trailing-twelve-month pace of -16.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 3.03M USD
- Year-over-year change
- -14.6%
- 4-year CAGR
- +26.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.03M | -14.6% |
| FY2024 | 2024-12-31 | 3.54M | +19.9% |
| FY2023 | 2023-12-31 | 2.96M | +93.6% |
| FY2022 | 2022-12-31 | 1.53M | +28.0% |
| FY2021 | 2021-12-31 | 1.19M | — |
Depreciation & Amortization vs competitors
How ARCT compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -16.2% is the 7th highest of 10, against a peer median of -3.9%.
- Depreciation & amortization amounts to 6.4% of revenue for ARCT, versus a peer median of 10.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $22.34M USD | -50.0% | -1.7% | 3.7% | |
| LTM Mar 2026 | $11.62M USD | -10.0% | +19.9% | 17.7% | |
| LTM Mar 2026 | $10.18M USD | +1.0% | +20.7% | — | |
| LTM Mar 2026 | €6.46M EUR | -64.9% | +1.1% | 4.1% | |
| LTM Mar 2026 | $2.99M USD | -3.9% | -18.4% | — | |
| LTM Mar 2026 | $2.88M USD | -16.2% | +25.6% | 6.4% | |
| LTM Mar 2026 | €2.72M EUR | -0.9% | +1.0% | 20.3% | |
| LTM Mar 2026 | $577.79K USD | — | +4.5% | 62.7% | |
| LTM Mar 2026 | $475K USD | +28.7% | +0.3% | — | |
| LTM Mar 2026 | $416K USD | +0.0% | +17.0% | — | |
| LTM Mar 2026 | $44K USD | -96.8% | -36.6% | 0.0% | |
| Peer median (excluding ARCT) | — | -3.9% | +1.1% | 10.9% | |
Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12.36M | 205.76M | 157.75M | 138.39M | 67.22M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.03M |
| Gross Profit | 12.36M | 205.76M | 157.75M | 138.39M | 64.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 95.5% |
| Research & Development | 173.76M | 147.75M | 192.13M | 195.16M | 112.21M |
| Selling, General & Admin | 41.45M | 46.07M | 52.87M | 52.82M | 46.08M |
| Operating Expenses | 215.21M | 193.58M | 235.95M | 234.06M | 139.15M |
| Depreciation & Amortization | 1.19M | 1.53M | 2.96M | 3.54M | 3.03M |
| EBITDA | (199.81M) | 15.17M | (24.17M) | (77.4M) | (62.76M) |
| EBITDA Margin | -1616.7% | 7.4% | -15.3% | -55.9% | -93.4% |
| Operating Income | (202.85M) | 12.18M | (78.21M) | (95.67M) | (74.96M) |
| Operating Margin | -1641.3% | 5.9% | -49.6% | -69.1% | -111.5% |
| Interest Income | 753K | 2.58M | 17.36M | 15.2M | 10.1M |
| Interest Expense | 2.67M | 3M | 767K | 0 | 0 |
| Other Income / Expenses | (822K) | (1.53M) | 50.32M | 14.72M | 9.17M |
| Income Before Tax | (203.67M) | 10.64M | (27.89M) | (80.95M) | (65.78M) |
| Pre-Tax Margin | -1648.0% | 5.2% | -17.7% | -58.5% | -97.9% |
| Income Tax Expense | 0 | 1.3M | 1.84M | (4K) | 0 |
| Net Income | (203.67M) | 9.35M | (29.73M) | (80.94M) | (65.78M) |
| Net Margin | -1648.0% | 4.5% | -18.8% | -58.5% | -97.9% |
| EPS (Basic) | (7.74) | 0.35 | (1.12) | (3.00) | (2.40) |
| EPS (Diluted) | (7.74) | 0.35 | (1.12) | (3.00) | (2.40) |
| Weighted Avg Shares | 26.32M | 26.45M | 26.63M | 27M | 27.39M |
| Weighted Avg Shares (Diluted) | 26.32M | 27.09M | 26.63M | 27M | 27.39M |
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
Intrinsic Alpha fair value
Locked
Current Price
$8.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.